Topics:
Breast Cancer • Medical Oncology
What is the data behind PARP inhibitors use in patients with somatic PALB2 mutations?
Should one consider use of PARP inhibitor in a patient with metastatic triple negative breast cancer and finding of a somatic PALB2 mutation on genomic profiling, progressing on three lines of standard chemotherapy.
Answer from: Medical Oncologist at Academic Institution
I would not use PARP inhibitors in breast cancer outside of a clinical trial.There are currently around 40 clinical trials actively studying several PARP inhibitors, many in phase III trials (olaparib, veliparib, niraparib, talazoparib). Olaparib 300 mg BID has been recently reported to improve PFS ...
Sign in or Register to read more